The first group is insomnia, a depressive condition with difficulty falling asleep associated with the pathogenesis of AD by inducing tau aggregation, amyloid-beta accumulation, neuroinflammation and decreases brain-derived neurotrophic factors (BDNFs) [127]. Here, MAPT is linked to insomnia measurement.